Peptide News & Regulatory Tracker
A neutral, dated record of the developments that actually matter — FDA approvals, the legal/compounding status of research peptides, major trial readouts, and safety signals. Every entry links to a primary source. We don't sell peptides; this is a reference, not advice.
Regulatory status changes quickly and varies by jurisdiction. Dates reflect when a development was reported. Nothing here is legal or medical advice — verify current status with the primary source and a qualified professional before acting.
- RegulatoryRecommendation only — not yet lawful
FDA advisory committee backs 6 of 7 peptides for the 503A compounding list
At its July 2026 meeting, the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon for the 503A bulk-substances list; only DSIP was rejected. Crucially, these are non-binding advisory recommendations — they do not approve any peptide or authorize compounding. The FDA must still complete formal notice-and-comment rulemaking (est. 8–12 months) before there is clear legal authority, so as of now compounding these peptides from bulk is not clearly lawful.
- Safety SignalUK label strengthened
MHRA strengthens acute-pancreatitis warnings on GLP-1 and GLP-1/GIP drugs
The UK's MHRA strengthened warnings for GLP-1 and dual GLP-1/GIP agonists (including semaglutide and tirzepatide) covering acute pancreatitis, including rare necrotising and fatal cases. The action followed 1,296 Yellow Card pancreatitis reports between 2007 and October 2025 (19 fatal, 24 necrotising). Note: randomized-trial meta-analyses have not shown a significant independent association, so this reflects pharmacovigilance caution rather than proven causation.
- Trial ReadoutPhase 3 / Breakthrough (MASH)
Survodutide meets primary endpoint in Phase 3 obesity trial; MASH breakthrough status
Boehringer Ingelheim and Zealand Pharma's survodutide (a glucagon/GLP-1 dual agonist) met the primary endpoint of its SYNCHRONIZE-1 Phase 3 obesity trial, with meaningful weight loss reported at 76 weeks. Survodutide also holds FDA Breakthrough Therapy designation for non-cirrhotic MASH (fatty-liver disease) with moderate-to-advanced fibrosis.
- FDA ApprovalFDA-approved
FDA approves Foundayo (orforglipron) — first oral small-molecule GLP-1 for weight loss
The FDA approved Eli Lilly's Foundayo (orforglipron), an oral GLP-1 receptor agonist, for obesity or overweight with a weight-related condition. Unlike peptide GLP-1s, orforglipron is a small molecule that can be taken any time of day without food or water restrictions — a significant convenience shift as the field moves toward pills.
- Trial ReadoutFiled with FDA (Dec 2025)
CagriSema misses non-inferiority vs tirzepatide in head-to-head trial
In the open-label REDEFINE-4 head-to-head trial, Novo Nordisk's CagriSema (cagrilintide + semaglutide) produced 23.0% weight loss vs 25.5% for tirzepatide 15 mg at 84 weeks, missing its primary non-inferiority endpoint. Novo had already filed CagriSema with the FDA in December 2025 based on the REDEFINE 1 and 2 trials; a decision is expected in late 2026.
- RegulatoryPolicy signal — not an enacted rule
HHS signals intent to move most restricted peptides toward Category 1
HHS Secretary Robert F. Kennedy Jr. announced an intent to move roughly 14 of 19 Category 2 peptides toward Category 1 for compounding consideration. Important context: this was a policy announcement, not an executed FDA rule — as of reporting, no formal FDA action had actually reclassified these peptides, and it did not by itself make compounding lawful.
- FDA ApprovalFDA-approved
FDA approves oral Wegovy (semaglutide 25 mg pill) for weight management
The FDA approved oral semaglutide 25 mg (oral Wegovy) for chronic weight management in obesity or overweight with a comorbidity, based on the OASIS trial program. It is the first oral GLP-1 pill approved for weight loss, with availability beginning early 2026.
- RegulatoryEnforcement action
FDA issues 50+ warning letters to GLP-1 compounders and sellers
The FDA published more than 50 warning letters targeting compounders and sellers making false claims about GLP-1 products (e.g. that compounded versions are "generic" or contain the "same active ingredient" as approved drugs). Notably, investigational compounds like retatrutide cannot be lawfully compounded at all — several letters name retatrutide products as unapproved and misbranded.
- Safety SignalEU label updated
EMA: NAION (sudden optic-nerve injury) is a "very rare" side effect of semaglutide
The EMA's safety committee (PRAC) concluded that non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of sudden vision loss, is a "very rare" side effect of semaglutide (up to 1 in 10,000 people) across Ozempic, Rybelsus, and Wegovy, and recommended updating the product information.
- RegulatoryCompounding no longer permitted
GLP-1 shortages officially end — mass compounding wind-down
The FDA removed tirzepatide (Dec 2024) and semaglutide (Feb 2025) from its drug-shortage list. With the shortages resolved, the temporary allowance for large-scale 503A/503B compounding of these GLP-1s ended (503A deadlines: tirzepatide Feb 2025, semaglutide Apr 2025). Routine mass compounding of these drugs is no longer permitted under the shortage provisions.